Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythroferrone as a Biomarker for rHuEpo Use
NCT03276910Phase 1Unknown
- Sponsor
- Athletes for Transparency
- Start
- Sep 2017
- Primary completion
- Dec 2017
01
Overview
Phase 1, randomised, double-blind trial of epoetin alfa in anemia (3 arms), sponsored by Athletes for Transparency. Primary endpoint: Erythroferrone at 29 days. Status: unknown.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT03276910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03276910.